Form 8-K REGENERON PHARMACEUTICAL For: Feb 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/8/2026
- Fiserv president resigns, interim leaders named for financial unit
- Nasdaq sinks as AI worries hit chipmakers
- Amazon launches bond sale seeking at least $25 billion
- Raymond James Starts SpaceX (SPCX) at Strong Buy, PT Street High $800
- Exclusive-China's DeepSeek developing its own AI chip, sources say
Regeneron (REGN) Misses Q4 GAAP EPS Views on R&D, Pipeline Expansion, but EYLEA Shaping-Up Well - Roth Capital
February 11, 2015 8:54 AM ESTRoth Capital affirms Regeneron (Nasdaq: REGN) at Buy with a price target of $461 following Q4, FY14 results reported earlier in the week.
Analyst Joseph Pantginis noted that Q4 GAAP EPS of $0.96 compared with his estimate of $1.36. The analyst attributed the miss to continued pipeline expansion as well as growing R&D reimbursement payments to Bayer and Sanofi."
Following results, Pantginis commented, We... More
